# Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor

> **NCT04454476** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 15 (estimated)

## Conditions studied

- Gastric Cancer
- Metaplasia
- Stage I Gastric Cancer
- Initial-onset Gastric Cancer

## Interventions

- **DRUG:** Trametinib treatment
- **PROCEDURE:** Endoscopy

## Key facts

- **NCT ID:** NCT04454476
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-11-09
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2024-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04454476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04454476, "Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04454476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*